• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Are direct-acting antivirals against hepatitis C virus infection not associated with the recurrence of hepatocellular carcinoma?针对丙型肝炎病毒感染的直接作用抗病毒药物与肝细胞癌复发无关吗？
Hepatobiliary Surg Nutr. 2019 Aug;8(4):423-425. doi: 10.21037/hbsn.2019.03.19.
2
Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C.直接作用抗病毒疗法可降低丙型肝炎肝硬化患者肝癌复发率。
Liver Int. 2017 Aug;37(8):1122-1127. doi: 10.1111/liv.13456. Epub 2017 May 25.
3
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.直接作用抗病毒治疗后慢性丙型肝炎患者的临床结局：一项前瞻性队列研究。
Lancet. 2019 Apr 6;393(10179):1453-1464. doi: 10.1016/S0140-6736(18)32111-1. Epub 2019 Feb 11.
4
Use of direct-acting antivirals for hepatitis C viral infection and association with intrahepatic cholangiocarcinoma: Is there a linkage?直接作用抗病毒药物用于丙型肝炎病毒感染及其与肝内胆管癌的关联：是否存在联系？
J Oncol Pharm Pract. 2019 Oct;25(7):1743-1748. doi: 10.1177/1078155218800147. Epub 2018 Sep 26.
5
Relationship of hepatitis B virus infection to the recurrence of hepatocellular carcinoma after direct acting antivirals.直接作用抗病毒药物治疗后乙型肝炎病毒感染与肝细胞癌复发的关系
Indian J Gastroenterol. 2017 May;36(3):235-238. doi: 10.1007/s12664-017-0755-3. Epub 2017 May 30.
6
Early development of de novo hepatocellular carcinoma after direct-acting agent therapy: Comparison with pegylated interferon-based therapy in chronic hepatitis C patients.直接作用抗病毒药物治疗后新发肝细胞癌的早期发生：与慢性丙型肝炎患者聚乙二醇干扰素治疗的比较
J Viral Hepat. 2018 Oct;25(10):1189-1196. doi: 10.1111/jvh.12918. Epub 2018 May 17.
7
Secondary prophylaxis of hepatocellular carcinoma: the comparison of direct-acting antivirals with pegylated interferon and untreated cohort.肝细胞癌的二级预防：直接抗病毒药物与聚乙二醇干扰素及未治疗队列的比较
J Viral Hepat. 2017 Jan;24(1):13-16. doi: 10.1111/jvh.12651. Epub 2016 Dec 1.
8
Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?我们是否应该在治疗肝癌的同时治愈丙型肝炎病毒？
Liver Int. 2018 Dec;38(12):2108-2116. doi: 10.1111/liv.13918. Epub 2018 Jul 21.
9
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.直接作用抗病毒药物治疗的丙型肝炎相关肝硬化中肝细胞癌的早期发生和复发。
J Hepatol. 2016 Oct;65(4):727-733. doi: 10.1016/j.jhep.2016.06.015. Epub 2016 Jun 24.
10
Pre- Versus Posttransplant Treatment of Hepatitis C Virus With Direct-Acting Antivirals in Liver Transplant Recipients: More Issues to be Solved.肝移植受者中丙型肝炎病毒直接作用抗病毒药物的移植前与移植后治疗：更多待解决的问题
Exp Clin Transplant. 2017 Feb;15(Suppl 1):1-5. doi: 10.6002/ect.mesot2016.L19.

本文引用的文献

1
Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.直接作用抗病毒治疗与多中心北美队列研究中肝细胞癌的复发无关。
Gastroenterology. 2019 May;156(6):1683-1692.e1. doi: 10.1053/j.gastro.2019.01.027. Epub 2019 Jan 18.
2
Hepatitis C virus-associated hepatocellular carcinoma after sustained virologic response.持续病毒学应答后丙型肝炎病毒相关肝细胞癌
World J Hepatol. 2018 Dec 27;10(12):898-906. doi: 10.4254/wjh.v10.i12.898.
3
Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection.预测 HCV 感染 DAA 治疗后 HCC 的极早期发生。
Hepatol Int. 2018 Nov;12(6):523-530. doi: 10.1007/s12072-018-9895-5. Epub 2018 Sep 21.
4
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.直接作用抗病毒药物治疗的丙型肝炎相关肝硬化中肝细胞癌的早期发生和复发。
J Hepatol. 2016 Oct;65(4):727-733. doi: 10.1016/j.jhep.2016.06.015. Epub 2016 Jun 24.
5
Interferon-free treatment for HCV-infected patients with decompensated cirrhosis.丙型肝炎病毒感染失代偿期肝硬化患者的无干扰素治疗
Hepatol Int. 2017 Jan;11(1):38-44. doi: 10.1007/s12072-016-9749-y. Epub 2016 Jun 9.
6
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.接受无干扰素治疗的丙型肝炎相关 HCC 患者早期肿瘤复发率高。
J Hepatol. 2016 Oct;65(4):719-726. doi: 10.1016/j.jhep.2016.04.008. Epub 2016 Apr 13.
7
Favorable Prognosis in Patients with Sustained Virological Response to Antiviral Therapy, Including Interferon, for Chronic Hepatitis C Before Hepatic Resection for Hepatocellular Carcinoma.在接受包括干扰素在内的抗病毒治疗后获得持续病毒学应答的慢性丙型肝炎患者，在接受肝细胞癌肝切除术前的良好预后。
Anticancer Res. 2015 Dec;35(12):6963-9.
8
Current management of patients with hepatocellular carcinoma.肝细胞癌患者的当前管理
World J Hepatol. 2015 Jul 28;7(15):1913-20. doi: 10.4254/wjh.v7.i15.1913.
9
APASL consensus statements and management algorithms for hepatitis C virus infection.亚太肝脏研究学会丙型肝炎病毒感染共识声明及管理算法
Hepatol Int. 2012 Apr;6(2):409-35. doi: 10.1007/s12072-012-9342-y. Epub 2012 Mar 1.
10
Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma.荟萃分析：干扰素改善肝癌消融或切除术的疗效。
Aliment Pharmacol Ther. 2010 Oct;32(7):851-8. doi: 10.1111/j.1365-2036.2010.04414.x.

Are direct-acting antivirals against hepatitis C virus infection not associated with the recurrence of hepatocellular carcinoma?

作者信息

Ogawa Masahiro, Kanda Tatsuo, Moriyama Mitsuhiko

机构信息

Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.

出版信息

Hepatobiliary Surg Nutr. 2019 Aug;8(4):423-425. doi: 10.21037/hbsn.2019.03.19.

DOI:10.21037/hbsn.2019.03.19
PMID:31489321
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6700000/
Abstract
摘要